Shares of Boston Scientific Corp. BSX slid 1.03% to $103.10 Tuesday, on what proved to be an all-around positive trading ...

Boston Scientific Corp. closed 2.80% short of its 52-week high of $107.17, which the company achieved on February 5th.

Boston Scientific has discontinued global sales of its Acurate neo2 and Acurate Prime transcatheter aortic valve replacement ...

Boston Scientific is pulling its latest transcatheter aortic heart valve platform from the worldwide market and said it will ...

Edwards Lifesciences (EW) stock and Medtronic (MDT) stock gain as Boston Scientific (BSX) halts sales of ACURATE heart valves ...

Boston Scientific said it would halt worldwide sales of its Acurate devices due to “increased clinical and regulatory ...

Boston Scientific ends global sales of ACURATE valves and halts FDA pursuit, citing rising regulatory burdens; expects to ...

According to the study’s abstract in The Lancet, TAVR with Acurate neo2 failed to meet non-inferiority. It also resulted in ...

Boston Scientific is throwing in the towel on its Acurate transcatheter aortic valve replacement, or TAVR, platform, citing rising costs of efforts to win regulatory approvals. Boston Scientific ...

The explanation for why the valve failed is too little, too late: Boston Scientific ended global sales of the device ...

Boston Scientific will eliminate jobs after discontinuing global sales of its Acurate aortic valve replacement systems that ...

The company also shared more details of its exit from the TAVR market and the impact of FDA layoffs on product review times.